Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04770896 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04770896 · ClinicalTrials.gov record · last posted 2026-08-25

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

Name: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab — clinical trial record (NCT04770896)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: IMbrave251

StatusActive, Not Recruiting

PhasePhase 3

SponsorHoffmann-La Roche

Started2021-04-26

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination.

Protocol amendment history 2 changes detected by DataLookout

2026-08-26

Primary completion pushed: 2026-06-30 → 2026-10-14

2026-08-26

Completion pushed: 2026-06-30 → 2026-10-14

Trial Details

NCT Number	NCT04770896
Lead Sponsor	Hoffmann-La Roche
Conditions	Unresectable Hepatocellular Carcinoma
Enrollment	557 participants
Start Date	2021-04-26
Primary Completion	2026-10-14 (estimated)
Study Completion	2026-10-14 (estimated)
Updated on ClinicalTrials.gov	2026-08-25